15 Best Biotech Stocks to Buy According to Billionaires

Page 3 of 13

11. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Billionaires: 13 

Dollar Value of Billionaire Holdings: $1,102,150,742 

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare serious diseases and stands eleventh among the best biotech stocks. It has four approved medications for the treatment of cystic fibrosis (CF), and one approved treatment for transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease (SCD). Clinical-stage initiatives for several conditions, such as TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency, are part of the company’s product pipeline.

Despite challenges in healthcare, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has outperformed the market and its biotech peers since 2022. With a stronghold in the cystic fibrosis market, the recent approval of Alyftrek, and patents secured into the 2030s, the company faces little competition, keeping investors bullish.

Investors are interested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) following the approval of Journavx, a non-opioid painkiller for acute pain. With strong efficacy and no addiction risk, it marks the first new class of pain medicine in over 20 years. The corporation reported strong Q4 2024 revenue of $2.91 billion, a 16% increase from Q4 2023. For the full year, it reached over $11 billion, surpassing growth expectations.

Page 3 of 13